Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-23 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0032 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2009-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5423e487b320d05684743b3544bd4c05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e8bfbb35c5fd85df596019d72e867c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032f9e6a4b82368681e71ef0cd59ca1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3772bba06bf5bc0c4d973c1620ba59b |
publicationDate |
2011-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2355847-A1 |
titleOfInvention |
Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
abstract |
The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis. |
priorityDate |
2008-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |